PureTech Health (LON:PRTC) Trading Up 14.2% - Should You Buy?

Key Points

• PureTech Health plc experienced a significant stock increase of 14.2%, reaching a last traded price of GBX 121.50 ($1.64).
• During the trading session, approximately 9 million shares changed hands, marking a 1,053% increase compared to its average daily volume.
• The company's market capitalization stands at £293.65 million with a P/E ratio of 714.71, highlighting a high valuation relative to earnings.

PureTech Health plc (LON:PRTC - )'s stock price was up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Up 14.2%

The company has a market capitalization of £293.65 million, a P/E ratio of 714.71 and a beta of 1.02. The business's fifty day moving average price is GBX 129.46 and its 200 day moving average price is GBX 129.83. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The stock was purchased at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by corporate insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.